Neogenomics Inc.

These forward-looking statements address various matters, including the Company s strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, expected synergies of the Pathline Acquisition, the timing, performance and anticipated benefits of collaboration, partnership and licensing activities, projected costs and capital expenditures, prospects and plans, and objectives of Management.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited to those related to revenue recognition and the determination of the amount expected to be collected, including estimates of implicit price concessions, accounts receivable and related allowances, contingencies, long-term debt, self-insurance exposures, useful lives and recovery of long-term assets and intangible assets, the fair value of assets and liabilities acquired in business combinations, the fair values of financial instruments, income taxes and valuation allowances, stock-based compensation, and impairment analysis of goodwill.

SEC original ↗Neogenomics Inc. — 10-Q Quarterly report10-QOct 28, 2026

If the Company undergoes a Fundamental Change (as defined in the 2026 Indenture), then noteholders may require the Company to repurchase their 2032 Convertible Notes at a cash repurchase price equal to the principal amount of the 2032 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the Fundamental Change Repurchase Date (as defined in the 2026 Indenture).

SEC original ↗Neogenomics Inc. — 10-Q Quarterly report10-QOct 28, 2026

The interest expense recognized on the 2032 Convertible Notes includes $ 0.6 million, $ 0.4 million and $ 47,000 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the three months ended September 30, 2026.

SEC original ↗Neogenomics Inc. — 10-Q Quarterly report10-QOct 28, 2026

The interest expense recognized on the 2032 Convertible Notes includes $ 0.7 million, $ 0.4 million and $ 50,000 for the contractual coupon interest, the amortization of the debt discount and the amortization of the debt issuance costs, respectively, for the nine months ended September 30, 2026.

SEC original ↗Neogenomics Inc. — 10-Q Quarterly report10-QOct 28, 2026

The effective interest rate on the 2032 Convertible Notes is 1.33 %, which includes the interest on the 2032 Convertible Notes and amortization of the debt discount and debt issuance costs.

SEC original ↗Neogenomics Inc. — 10-Q Quarterly report10-QOct 28, 2026

Third Quarter 2025 Highlights As Compared To Third Quarter 2024 Consolidated revenue increased 12% to a record $188 million, driven by Clinical revenue growth of 18% Net loss increased 53% to $27 million Adjusted EBITDA was positive $12 million, a decline of 9% from prior year During the third quarter, we again delivered strong clinical test volumes and revenue while advancing our long-term growth initiatives in therapy selection and MRD two of the largest and fastest growing areas of cancer testing with significant unmet needs, stated Tony Zook, CEO of NeoGenomics.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Total revenue of $188 million increased 12% year-over-year, driven by the continued expansion of our clinical business, which grew by 18%.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Our relentless focus on the customer experience, which is enabled by our broad, oncology-centric test menu, world class commercial organization, and balanced geographic footprint, continues to differentiate us in the community setting, where approximately 80% of cancer care is delivered.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

This increase reflects a mix shift towards higher value tests, including NGS, and the positive impact of strategic reimbursement initiatives.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

These forward-looking statements address various matters, including the Company s strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, expected synergies of the Pathline Acquisition, the timing, performance and anticipated benefits of collaboration, partnership and licensing activities, projected costs and capital expenditures, prospects and plans, and objectives of Management.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

com, for a discussion of these and other risks and uncertainties.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Our business is subject to substantial risks and uncertainties, including those referenced above.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Definitions of Non-GAAP Measures Non-GAAP Adjusted EBITDA Adjusted EBITDA is defined by NeoGenomics as net (loss) income from continuing operations before (i) interest income, (ii) interest expense, (iii) tax (benefit) or expense, (iv) depreciation and amortization expense, (v) stock-based compensation expense, and, if applicable in a reporting period, (vi) CEO transition costs, (vii) acquisition and integration related expenses, (viii) restructuring charges, (ix) impairment charges, (ix) intellectual property ( IP ) litigation costs, and (x) other significant or non-operating (income) or expenses, net.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Non-GAAP Adjusted Net (Loss) Income Adjusted net (loss) income is defined by NeoGenomics as net (loss) income from continuing operations plus (i) amortization of intangible assets, (ii) stock-based compensation expense, and, if applicable in a reporting period, (iii) CEO transition costs, (iv) acquisition and integration related expenses, (v) restructuring charges, (vi) impairment charges, (vii) IP litigation costs, and (viii) other significant or non-operating (income) or expenses, net.

SEC original ↗Neogenomics Inc. — Earnings release (8-K exhibit)EX-99Oct 28, 2025